![National Cancer Institute (NCI)](https://trials-media.s3.amazonaws.com/orgs/national-cancer-institute-nci.jpeg)
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's...
Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell Lymphoma1 moreDrugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Valproic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine together with valproic acid may be an effective treatment for non-Hodgkin's lymphoma. This phase I trial is studying the side effects and best dose of decitabine and valproic acid in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
![Fred Hutchinson Cancer Center](https://trials-media.s3.amazonaws.com/orgs/fred-hutchinson-cancer-center.jpeg)
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant...
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in Remission12 moreThis randomized phase III trial is studying total-body irradiation (TBI) and fludarabine phosphate to see how it works compared with TBI alone followed by donor stem cell transplant in treating patients with hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening. It is not yet known whether TBI followed by donor stem cell transplant is more effective with or without fludarabine phosphate in treating hematologic cancer.
![National Cancer Institute (NCI)](https://trials-media.s3.amazonaws.com/orgs/national-cancer-institute-nci.jpeg)
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas...
Adult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell Lymphoma43 morePhase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating patients who have metastatic or advanced solid tumors or lymphomas. MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Isotretinoin may help cancer cells develop into normal cells. MS-275 may increase the effectiveness of isotretinoin by making cancer cells more sensitive to the drug. MS-275 and isotretinoin may also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer. Combining MS-275 with isotretinoin may kill more cancer cells
![NCIC Clinical Trials Group](https://trials-media.s3.amazonaws.com/orgs/ncic-clinical-trials-group.jpeg)
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating patients with non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying four different combination chemotherapy regimens and rituximab to see how well they work compared to four different combination chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.
![Alliance for Clinical Trials in Oncology](https://trials-media.s3.amazonaws.com/orgs/alliance-for-clinical-trials-in-oncology.jpeg)
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma...
LymphomaRATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with progressive non-Hodgkin's lymphoma.
![Fox Chase Cancer Center](https://trials-media.s3.amazonaws.com/orgs/fox-chase-cancer-center.jpeg)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma...
LeukemiaLymphomaRATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining epirubicin with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with rituximab in treating patients who have relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
![National Cancer Institute (NCI)](https://trials-media.s3.amazonaws.com/orgs/national-cancer-institute-nci.jpeg)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive...
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)62 moreThis phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
![Gilead Sciences](https://trials-media.s3.amazonaws.com/orgs/gilead-sciences.jpeg)
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
Non-Hodgkin's LymphomaLymphoma1 moreThe purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
![German High-Grade Non-Hodgkin's Lymphoma Study Group](https://trials-media.s3.amazonaws.com/orgs/german-high-grade-non-hodgkins-lymphoma-study-group.jpeg)
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's...
Non-Hodgkin's Lymphoma (NHL)According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2 or 3) results in a better time to treatment failure (TTTF)
![Amgen](https://trials-media.s3.amazonaws.com/orgs/amgen.jpeg)
Treatment for Subjects With Non-Hodgkin's Lymphoma
Non-Hodgkin's LymphomaThis multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count (ANC) support would assist in allowing the planned dose-on-time (PDOT) of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) chemotherapy with Rituximab every 14 days in subjects with aggressive B-cell Non-Hodgkin's Lymphoma by reducing the duration of neutropenia and incidence of febrile neutropenia.